DNA drug for treating tumors by targeted immune system and application thereof

Abstract

The invention discloses a DNA drug for treating tumors by a targeted immune system and application thereof, and relates to the technical field of biological medicines. The drug comprises effective components including an expression vector and a human immunocompetence factor gene segment loaded on the expression vector, the expression vector is a non-replication gene vector, and tissue specific promoters loaded on the expression vector are different when the expression vector is applied to treatment of tumors of different tissue types. The human immunocompetence factor is a human T cell co-activation factor, is subjected to ectopic expression on the surface of a tumor cell, and is used for targeting system immune response. After intratumoral injection administration, T cell co-activation factor ectopic high expression on tumor cell membranes of different tissue types is realized under the regulation and control of different tissue specific promoters, and T cells interact with ligands / receptors on the surfaces of T cells to activate the systematic immune response of the T cells to tumors.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to a DNA drug targeting the immune system to treat tumors and its application. Background technique [0002] Cancer seriously threatens human health. In recent years, DNA vaccines have been very active in the development of immunotherapy for tumors. Anti-tumor DNA vaccines, also known as nucleic acid vaccines, use gene recombination technology to directly combine genes encoding tumor-specific antigens or tumor-associated antigens with expression vectors, introduce them into organisms, express them in host cells, and induce the host to produce the tumor-associated antigens. The immune response to tumor-associated antigens can achieve the purpose of preventing and treating tumors. [0003] Although the current anti-tumor DNA vaccine has good application prospects in clinical trials, it still faces many challenges in order to become a powerful treatment in the field of tumor immu...

AI Technical Summary

Problems solved by technology

For example, after intravenous administration, DNA interacts with blood components, which in turn may strongly affect its cell-binding properties, resulting in a significant decrease in the amount of DNA in tissue cells, so the expression of antigens is significantly insufficient and cannot effectively activate the immune system

Images